The White House recently announced a landmark deal with pharmaceutical companies Eli Lilly and Nordisk that will impact Medicare beneficiaries and others in the coming months. The agreement cuts prices for GLP-1 receptor agonists, such as Ozempic and Wegovy, while expanding Medicare coverage for these weight-loss medications. The news is a turnaround from a Trump administration announcement earlier this year blocking Medicare from covering obesity drugs.
With the new deal, Medicare will no longer only cover these drugs for diabetes or heart issues, but for obesity itself, potentially saving beneficiaries hundreds of dollars each month.
